Revenue Update on Conatus Pharmaceuticals Inc(NASDAQ:CNAT)

Conatus Pharmaceuticals Inc(NASDAQ:CNAT) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $799.046K. Analysts estimated a revenue of $1.670M. The revenues were -52.15% below the estimates. Earnings per share were $-0.35. The reported EPS was below estimates by -34.62%. Analysts had estimated an EPS of $-0.26.

Conatus Pharmaceuticals Inc (CNAT) made into the market gainers list on Fridays trading session with the shares advancing 2.18% or 0.1 points. Due to strong positive momentum, the stock ended at $4.69, which is also near the day’s high of $4.799. The stock began the session at $4.6 and the volume stood at 2,54,417 shares. The 52-week high of the shares is $6.3 and the 52 week low is $1.4533. The company has a current market capitalization of $122 M and it has 2,60,67,154 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Apr 10, 2015, Daniel L Kisner (director) purchased 4,000 shares at $5.75 per share price.

Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound emricasan is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases which are enzymes that mediate inflammation and apoptosis. It is conducting a clinical program to demonstrate the therapeutic benefit of emricasan in patients with chronic liver disease across the spectrum of liver disease including liver cirrhosis (LC); liver cirrhosis with portal hypertension (PH); post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR) and non-alcoholic fatty liver disease (NAFLD) including patients with inflammatory and/or fibrotic non-alcoholic steatohepatitis (NASH).

Add Comment